[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Global Markets Direct: Market Research Reports

Global Markets Direct is a cutting-edge provider of market research and business consultancies for a wide range of customers worldwide.

A team of analytics is capable to produce all sorts of market information and carry out extensive industry research using unique data and reliable sources to let customers know who they are at the market. Global Markets Direct has profound analytical experience in researching the industries and preparing customized reports across many specific fields.

The company is distinguished by its high-quality consulting products and close inspection of the issues under study. Diligent efforts of the experts make every piece of business information an exclusive source of feasible solutions and valuable advice.

With a commitment to serve every client need, Global Markets Direct collects and interprets the materials for the analysis, uses methods of primary and secondary research and develops one of a kind data packages for global clients. They are able to cover the tones of industry-related information to assist customers in taking the right business decisions and developing their strategic plans.

Under the supervision of skillful managers and experts, business analysts produce reports that include:

  • Product portfolio
  • Potentially strong market reviews
  • Competitive analytics
  • Prospect partners
  • Mergers and acquisitions project data
  • Latest trends across a particular industry area
  • Research and development strategies
  • The analysis of new customers
  • A set of remedial measures for projects

They will search for new partners and highlight the current business issues plus develop new strategies and tactical steps to help you take the lead in the industry where you operate.

Publications found: 5,853
Sort by:

Fibromyalgia - Pipeline Review, H1 2018

US$ 2,000.00

... . The Fibromyalgia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Fibromyalgia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...

January 2018 68 pages

Constipation - Pipeline Review, H1 2018

US$ 2,000.00

... releases. The Constipation (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Constipation and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...

January 2018 117 pages

Primary Biliary Cirrhosis - Pipeline Review, H1 2018

US$ 2,000.00

... releases. The Primary Biliary Cirrhosis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Primary Biliary Cirrhosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...

January 2018 111 pages

Microscopic Polyangiitis (MPA) - Pipeline Review, H1 2018

US$ 2,000.00

... releases. The Microscopic Polyangiitis (MPA) (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Microscopic Polyangiitis (MPA) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...

January 2018 42 pages

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Pipeline Review, H1 2018

US$ 3,500.00

... being developed by Companies/Universities. It also reviews key players involved in Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics development with ...

January 2018 96 pages

Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Pipeline Review, H1 2018

US$ 3,500.00

... Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

January 2018 83 pages

Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Pipeline Review, H1 2018

US$ 3,500.00

... Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

January 2018 75 pages

P2X Purinoceptor 3 (P2RX3) - Pipeline Review, H1 2018

US$ 3,500.00

... P2X Purinoceptor 3 (P2RX3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

January 2018 53 pages

Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) - Pipeline Review, H1 2018

US$ 3,500.00

... effectively by identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) development landscape Develop and design in-licensing ...

January 2018 35 pages

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Pipeline Review, H1 2018

US$ 3,500.00

... Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

January 2018 55 pages

P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Pipeline Review, H1 2018

US$ 3,500.00

... P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

January 2018 34 pages

Cluster Headache Syndrome - Pipeline Review, H1 2018

US$ 2,000.00

... . The Cluster Headache Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Cluster Headache Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development ...

January 2018 49 pages

72 kDa Type IV Collagenase (Matrix Metalloproteinase 2 or Gelatinase A or Neutrophil Gelatinase or 72 kDa Gelatinase or TBE 1 or MMP2 or EC 3.4.24.24) - Pipeline Review, H1 2018

US$ 3,500.00

... key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding 72 kDa Type IV Collagenase (Matrix Metalloproteinase 2 or Gelatinase A or Neutrophil Gelatinase or 72 kDa Gelatinase or TBE 1 or MMP2 or EC 3.4.24.24) development landscape Develop ...

January 2018 33 pages

Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Pipeline Review, H1 2018

US$ 3,500.00

... Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

January 2018 53 pages

Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) - Pipeline Review, H1 2018

US$ 3,500.00

... and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) development landscape Develop and design in-licensing and ...

January 2018 39 pages

Encephalitis - Pipeline Review, H1 2018

US$ 2,000.00

... . The Encephalitis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Encephalitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...

January 2018 34 pages

Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Pipeline Review, H1 2018

US$ 3,500.00

... Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

January 2018 41 pages

Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Pipeline Review, H1 2018

US$ 3,500.00

... Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

January 2018 74 pages

Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) - Pipeline Review, H1 2018

US$ 3,500.00

... by identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) development landscape Develop and ...

January 2018 65 pages

Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) - Pipeline Review, H1 2018

US$ 3,500.00

... Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

January 2018 44 pages

Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Pipeline Review, H1 2018

US$ 3,500.00

... Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

January 2018 35 pages

Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Pipeline Review, H1 2018

US$ 3,500.00

... Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

January 2018 39 pages

Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) - Pipeline Review, H1 2018

US$ 3,500.00

... reviews Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) targeted therapeutics under development ...

January 2018 86 pages

Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Pipeline Review, H1 2018

US$ 3,500.00

... also reviews key players involved in Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) targeted therapeutics development with respective active and dormant ...

January 2018 77 pages

Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) - Pipeline Review, H1 2018

US$ 3,500.00

... key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) development ...

January 2018 40 pages

Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Pipeline Review, H1 2018

US$ 3,500.00

... by identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) development landscape Develop and ...

January 2018 80 pages

Ovarian Cancer - Pipeline Review, H2 2017

US$ 2,500.00

... releases. The Ovarian Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Ovarian Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...

December 2017 2232 pages

Exocrine Pancreatic Insufficiency - Pipeline Review, H2 2017

US$ 2,000.00

... releases. The Exocrine Pancreatic Insufficiency (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Exocrine Pancreatic Insufficiency and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...

December 2017 44 pages

Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Pipeline Review, H2 2017

US$ 3,500.00

... by identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) development landscape Develop and design ...

December 2017 181 pages

Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Pipeline Review, H2 2017

US$ 3,500.00

... Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

December 2017 60 pages

E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Pipeline Review, H2 2017

US$ 3,500.00

... by identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) development landscape Develop and ...

December 2017 75 pages

Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Pipeline Review, H2 2017

US$ 3,500.00

... Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

December 2017 48 pages

Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Pipeline Review, H2 2017

US$ 3,500.00

... by identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) development landscape Develop and design ...

December 2017 63 pages

Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Pipeline Review, H2 2017

US$ 3,500.00

... key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) development ...

December 2017 55 pages

Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Pipeline Review, H2 2017

US$ 3,500.00

... Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

December 2017 115 pages

Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) - Pipeline Review, H2 2017

US$ 3,500.00

... Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

December 2017 43 pages

Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Pipeline Review, H2 2017

US$ 3,500.00

... by identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) development landscape Develop and ...

December 2017 71 pages

Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Pipeline Review, H2 2017

US$ 3,500.00

... by identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) development landscape Develop and design ...

December 2017 78 pages

N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) - Pipeline Review, H2 2017

US$ 3,500.00

... N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

December 2017 48 pages

Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) - Pipeline Review, H2 2017

US$ 3,500.00

... key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) development ...

December 2017 61 pages

Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) - Pipeline Review, H2 2017

US$ 3,500.00

... identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) development landscape Develop ...

December 2017 38 pages

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2017

US$ 3,500.00

... Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

December 2017 57 pages

Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) - Pipeline Review, H2 2017

US$ 3,500.00

... key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) development ...

December 2017 42 pages

Alpha L-Iduronidase (IDUA or EC 3.2.1.76) - Pipeline Review, H2 2017

US$ 3,500.00

... Alpha L-Iduronidase (IDUA or EC 3.2.1.76) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

December 2017 48 pages

Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Pipeline Review, H2 2017

US$ 3,500.00

... , this report also reviews key players involved in Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) targeted therapeutics development with respective active and ...

December 2017 52 pages

Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) - Pipeline Review, H2 2017

US$ 3,500.00

... key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) development landscape Develop and ...

December 2017 41 pages

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Pipeline Review, H2 2017

US$ 3,500.00

... Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

December 2017 89 pages

Free Fatty Acid Receptor 4 (G Protein Coupled Receptor 120 or G Protein Coupled Receptor 129 or G Protein Coupled Receptor GT01 or Omega 3 Fatty Acid Receptor 1 or G Protein Coupled Receptor PGR4 or GPR120 or GPR129 or FFAR4) - Pipeline Review, H2 2017

US$ 3,500.00

... reviews key players involved in Free Fatty Acid Receptor 4 (G Protein Coupled Receptor 120 or G Protein Coupled Receptor 129 or G Protein Coupled Receptor GT01 or Omega 3 Fatty Acid Receptor 1 or G Protein Coupled Receptor PGR4 or GPR120 or GPR129 or FFAR4) targeted therapeutics development with respective ...

December 2017 29 pages

Smoking Addiction - Pipeline Review, H2 2017

US$ 2,000.00

... . The Smoking Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Smoking Addiction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...

December 2017 89 pages

Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline Review, H2 2017

US$ 2,000.00

... . The Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Vasomotor Symptoms of Menopause (Hot Flashes) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...

December 2017 57 pages

Filters

Search

Categories

2,264
2,910
126
9
6
1
1
1
4
522
3
6

Publishers

5,853

Regions

5,853

Price

β€”

Date

β€”

Pages

β€”

Offers